Sparing of Organs at Risk in High Dose Rate Brachytherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01681342|
Recruitment Status : Completed
First Posted : September 7, 2012
Last Update Posted : July 25, 2013
Cervix carcinoma is a common malignancy. Radiation therapy still remains a major treatment for patients with carcinoma cervix. Conventional treatment with radiation therapy includes a combination of external beam radiation therapy and intracavitary treatment. Low dose rate intracavitary brachytherapy treatment is already well studied. But high dose rate brachytherapy is a relatively new alternative.
In brachytherapy, major developments have been made in the integration of 3D imaging and computerized 3D treatment planning. Medical imaging improvements allowed for better definition of tumoral volumes and organs at risk.
The GYN GEC-ESTRO published recommendations on the 3D imaging for better characterization of these volumes. Improvements in CT-SCan and lately in RMN had lead to a better definition of volums of interest (tumor and his extensions and organs at risk : bladder, rectum, sigmoidis, small bowels). RMN is the imaging standard in the evaluation of tumoral extension in cervix cancer. However its use is not easy in many brachytherapy departments.
This study will evaluate the feasibility and sparing of organs at risk for high dose rate brachytherapy if volume delineation is done at each of the two sessions performed with 3D RMN.
|Condition or disease|
|Cervical Carcinoma Stage IB to IV|
After 60 Gy are delivered with Intensity Modulated Radiation Therapy (IMRT), the brachytherapy in high dose rate will deliver 15 Gy to the CTVhr (high risk CTV) in two sessions.
A clinical examination and an RMN are performed at the end of the external radiation to evaluate the residual tumoral volume. Two HDR brachytherapy sessions are then performed.
During the first session, a CT-Scan and an RMN will be performed after the fletcher application. A second CT-Scan will be performed during the second treatment session to create new volumes and to improve organs at risk sparing.
|Study Type :||Observational|
|Actual Enrollment :||24 participants|
|Official Title:||Prospective Study on the Sparing of Organs at Risk in High Dose Rate Brachytherapy for Cervix Cancer|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||February 2013|
|Actual Study Completion Date :||February 2013|
- Evaluation of the sparing of organs at risk with a delineation at each session and the CTVhr volume modification [ Time Frame: At 8 weeks of external radiotherapy ]To record the irradiated volumes modifications of each OAR at each session and the CTV volume modification.
- Evaluation of medical imaging with CT-Scan and RMN for cervix cancer [ Time Frame: At 8 weeks of external radiotherapy ]
- Interest of RMN sequences Water and T2 for the definition of volumes
- Evaluation of imaging registration on the planning treatment system based on the brachytherapy applicator for the precision of volumes delineation
- Evaluate the interest of TDM and RMN for volumes delineation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01681342
|Centre Oscar Lambret|
|Lille, France, 59020|
|Study Director:||Philippe Nickers, MD, PhD||Centre Oscar Lambret|